Giancarlo Bisagni

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/ <i>neu</i> –Positive Metastatic Breast Cancer

Antonino Musolino, Nadia Naldi, Beatrice Bortesi et al. · Journal of Clinical Oncology · 2008 · 949 citations · Full text

Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study

Valentina Guarneri, Antonio Frassoldati, Alberto Bottini et al. · Journal of Clinical Oncology · 2012 · 366 citations · Full text

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

Lucia Del Mastro, Sabino De Placido, Paolo Bruzzi et al. · The Lancet · 2015 · 196 citations

Breast Oncology, Medicine, Dose-dense Chemotherapy +6

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

Luca Gianni, Giancarlo Bisagni, Marco Colleoni et al. · The Lancet Oncology · 2018 · 167 citations

Breast Oncology, Medicine, Pharmacology +7

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With <i>ERBB2/HER2</i> -Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial

Luca Gianni, Mauro Mansutti, Antonio Antón et al. · JAMA Oncology · 2018 · 153 citations · Full text